logo-loader
viewIntegumen

Open Orphan sells remaining stake in Integumen

Open Orphan held a small stake in Integumen through its recent reverse takeover of Venn Life Sciences, which spun out Integumen a few years ago

share certificate
The sale eliminates any possibility of a stock overhang, which can weigh on a share price

Open Orphan PLC (LON:ORPH) has sold its remaining shares in cosmetics testing group Integumen PLC (LON:SKIN).

Integumen was spun out of Venn Life Sciences – the forerunner to Open Orphan – back in 2016, which left the latter with a stake in the new business.

READ: Integumen posts 1,200% rise in first-half revenue

After Open Orphan’s recent reverse takeover of Venn, the new management has decided to sell its holding.

Integumen said the shares, equating to a holding of around 3.1%, had been sold to existing long-term shareholders, “thereby eliminating any overhang on the open market”.

Integumen shares were up 1.4% to 2.08p, valuing the company at just over £20mln.

Quick facts: Integumen

Price: 1.78 GBX

AIM:SKIN
Market: AIM
Market Cap: £19.09 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Integumen named herein, including the promotion by the Company of Integumen in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Integumen PLC 'the number one thought leader in skin microbiome and AI'

Integumen PLC's (LON:SKIN) Gerry Brandon recaps on 2019 and key highlights including the acquisition of RinoCloud and the deal done with Parity Group. Brandon adds that they're intending to double the size of its Labskin laboratory in York, currently at 3,162 square feet, which could provide...

on 20/12/19

2 min read